Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors

Article
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.

Cancer Network spoke with Adi Diab, MD, of The University of Texas MD Anderson Cancer Center, regarding the results of the phase I/II PIVOT-02 trial. He and fellow investigators are exploring the association between baseline tumor immune signatures and response to bempegaldesleukin (NKTR-214) and nivolumab in patients with advanced solid tumors. The results (abstract 2623) were presented at ASCO 2019.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Related Content
Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia

Ariana Pelosci
June 13th 2025
Article

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Polatuzumab Vedotin Combo Improves OS Vs Rituximab/Chemo in R/R DLBCL

Polatuzumab Vedotin Combo Improves OS Vs Rituximab/Chemo in R/R DLBCL

Ariana Pelosci
June 13th 2025
Article

Patients with R/R DLBCL given polatuzumab vedotin, rituximab, gemcitabine, and oxaliplatin had an OS of 19.5 months.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

Ashley Chan
June 12th 2025
Article

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.

Tivozanib Shows Efficacy in Pretreated Metastatic RCC

Kyle Doherty
June 11th 2025
Article

There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.